title: Recurrent neutropenia due to dopamine agonists in a patient with microprolactinoma.
abstract: OBJECTIVE
  The objective of our case report is to increase the awareness of neutropenia as a rare but potentially serious adverse outcome of commonly used dopamine agonists for the treatment of prolactinomas.
  
  
  METHODS
  This report reviews the clinical history, diagnosis, investigations, and drug treatment of our patient.
  
  
  RESULTS
  Neutropenia was recurrent after changing to various different dopamine agonists necessitating surgical treatment of a prolactinoma.
  
  
  CONCLUSIONS
  This case serves a reminder of this adverse drug reaction. Considering the significant impact and potentially a life threatening outcome, we advocate routine monitoring of full blood count prior to and during the treatment with dopamine agonists.
authors.affiliation: Peterborough City Hospital, Peterborough, United Kindgom.
authors.forename: Muhammad Imran
authors.initials: MI
authors.lastname: Butt
authors.forename: Najeeb
authors.initials: N
authors.lastname: Waheed
mesh_terms: D000328:Adult; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced*; D010911:Pituitary Neoplasms / Q000188:drug therapy; D015175:Prolactinoma / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists